XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue (Disaggregation of Revenue by Geographical Region) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 26, 2025 | Sep. 27, 2024 | Sep. 26, 2025 | Sep. 27, 2024
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | $ 6,053 | $ 5,798 | $ 17,730 | $ 17,337
Recurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 5,017 | 4,777 | 14,803 | 14,261
Nonrecurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,036 | 1,021 | 2,927 | 3,076
North America |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 2,580 | 2,456 | 7,600 | 7,522
Western Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,396 | 1,320 | 4,247 | 3,965
Other developed markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 316 | 299 | 888 | 894
High-growth markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,761 | 1,723 | 4,995 | 4,956
Operating segments | Biotechnology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,798 | 1,653 | 5,260 | 4,890
Operating segments | Biotechnology | Recurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,590 | 1,422 | 4,741 | 4,209
Operating segments | Biotechnology | Nonrecurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 208 | 231 | 519 | 681
Operating segments | Biotechnology | North America |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 624 | 503 | 1,779 | 1,624
Operating segments | Biotechnology | Western Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 587 | 587 | 1,861 | 1,700
Operating segments | Biotechnology | Other developed markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 89 | 78 | 235 | 238
Operating segments | Biotechnology | High-growth markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 498 | 485 | 1,385 | 1,328
Operating segments | Life Sciences |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,792 | 1,782 | 5,249 | 5,297
Operating segments | Life Sciences | Recurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,216 | 1,228 | 3,566 | 3,628
Operating segments | Life Sciences | Nonrecurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 576 | 554 | 1,683 | 1,669
Operating segments | Life Sciences | North America |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 728 | 796 | 2,211 | 2,362
Operating segments | Life Sciences | Western Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 392 | 365 | 1,164 | 1,111
Operating segments | Life Sciences | Other developed markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 130 | 120 | 371 | 361
Operating segments | Life Sciences | High-growth markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 542 | 501 | 1,503 | 1,463
Operating segments | Diagnostics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 2,463 | 2,363 | 7,221 | 7,150
Operating segments | Diagnostics | Recurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 2,211 | 2,127 | 6,496 | 6,424
Operating segments | Diagnostics | Nonrecurring revenue |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 252 | 236 | 725 | 726
Operating segments | Diagnostics | North America |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 1,228 | 1,157 | 3,610 | 3,536
Operating segments | Diagnostics | Western Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 417 | 368 | 1,222 | 1,154
Operating segments | Diagnostics | Other developed markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | 97 | 101 | 282 | 295
Operating segments | Diagnostics | High-growth markets |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Sales | $ 721 | $ 737 | $ 2,107 | $ 2,165

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=dhr_RevenuefromContractwithCustomerMeasurementRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dhr_RevenuefromContractwithCustomerMeasurementNonrecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_WesternEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_OtherDevelopedMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_HighGrowthMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_BiotechnologySegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |